Treatment-related myelodysplasia following fludarabine combination chemotherapy
Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia. Although myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) are rare following fludarabine monotherapy, the risk of these diseases may potentially be increased when fludarabine is combined with cyclophospha...
Gespeichert in:
| Veröffentlicht in: | Haematologica (Roma) 2006-11, Vol.91 (11), p.1546-1550 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1550 |
|---|---|
| container_issue | 11 |
| container_start_page | 1546 |
| container_title | Haematologica (Roma) |
| container_volume | 91 |
| creator | Tam, CS Seymour, JF Prince, HM Kenealy, M Wolf, M Januszewicz, EH Westerman, D |
| description | Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Although myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) are rare following fludarabine monotherapy, the risk of these diseases may potentially be increased when fludarabine is combined with cyclophosphamide or mitoxantrone due to synergistic effects on the inhibition of DNA repair. Among 137 patients treated with fludarabine combination regimens, ten patients developed MDS/sAML, including one who had received no other therapy. Six patients had abnormalities of chromosomes 5 and/or 7. The crude rate of MDS/sAML was 2.5% for previously untreated patients, and 9.3% for pretreated patients (p=0.28). The rate of MDS/sAML following fludarabine combination therapy is higher than that previously reported for fludarabine monotherapy. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_17082012</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17082012</sourcerecordid><originalsourceid>FETCH-LOGICAL-h271t-82b07856467f8661bb9d9a071f655b4b8e55f310807b13504457af2ec58df4a3</originalsourceid><addsrcrecordid>eNpFz8lqwzAUBVBRWpo07S8Ub0pXBknWuCyhEwSy8d482VKsIg9IDsZ_X0NSCg_u5nC57wZtCdc0V5KSW7TFhca5wFJt0ENKPxhTrLW8RxsisaKY0C06ltHC1Nl-yqMNMNkm6xYbhmZJY4DkIXNDCMPs-1PmwrmBCMb3NquHbk2Y_NBndWu7YWpthHF5RHcOQrJP19yh8uO93H_lh-Pn9_7tkLdUkilX1KyzuGBCOiUEMUY3GrAkTnBumFGWc1cQrLA0pOCYMS7BUVtz1TgGxQ49X2rHs-lsU43RdxCX6u-xFbxcAaQagovQ1z79O0UFw5ys7vXiWn9qZx9tlToIYa2l1TzPmlRkPc5E8QtnHWYy</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Treatment-related myelodysplasia following fludarabine combination chemotherapy</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Tam, CS ; Seymour, JF ; Prince, HM ; Kenealy, M ; Wolf, M ; Januszewicz, EH ; Westerman, D</creator><creatorcontrib>Tam, CS ; Seymour, JF ; Prince, HM ; Kenealy, M ; Wolf, M ; Januszewicz, EH ; Westerman, D</creatorcontrib><description>Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Although myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) are rare following fludarabine monotherapy, the risk of these diseases may potentially be increased when fludarabine is combined with cyclophosphamide or mitoxantrone due to synergistic effects on the inhibition of DNA repair. Among 137 patients treated with fludarabine combination regimens, ten patients developed MDS/sAML, including one who had received no other therapy. Six patients had abnormalities of chromosomes 5 and/or 7. The crude rate of MDS/sAML was 2.5% for previously untreated patients, and 9.3% for pretreated patients (p=0.28). The rate of MDS/sAML following fludarabine combination therapy is higher than that previously reported for fludarabine monotherapy.</description><identifier>ISSN: 0390-6078</identifier><identifier>EISSN: 1592-8721</identifier><identifier>PMID: 17082012</identifier><language>eng</language><publisher>Pavia: Haematologica</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Cohort Studies ; Drug Therapy, Combination ; Female ; Hematologic and hematopoietic diseases ; Humans ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulinopathies ; Immunopathology ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical sciences ; Middle Aged ; Myelodysplastic Syndromes - chemically induced ; Myelodysplastic Syndromes - epidemiology ; Myelodysplastic Syndromes - therapy ; Vidarabine - adverse effects ; Vidarabine - analogs & derivatives</subject><ispartof>Haematologica (Roma), 2006-11, Vol.91 (11), p.1546-1550</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18264051$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17082012$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tam, CS</creatorcontrib><creatorcontrib>Seymour, JF</creatorcontrib><creatorcontrib>Prince, HM</creatorcontrib><creatorcontrib>Kenealy, M</creatorcontrib><creatorcontrib>Wolf, M</creatorcontrib><creatorcontrib>Januszewicz, EH</creatorcontrib><creatorcontrib>Westerman, D</creatorcontrib><title>Treatment-related myelodysplasia following fludarabine combination chemotherapy</title><title>Haematologica (Roma)</title><addtitle>Haematologica</addtitle><description>Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Although myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) are rare following fludarabine monotherapy, the risk of these diseases may potentially be increased when fludarabine is combined with cyclophosphamide or mitoxantrone due to synergistic effects on the inhibition of DNA repair. Among 137 patients treated with fludarabine combination regimens, ten patients developed MDS/sAML, including one who had received no other therapy. Six patients had abnormalities of chromosomes 5 and/or 7. The crude rate of MDS/sAML was 2.5% for previously untreated patients, and 9.3% for pretreated patients (p=0.28). The rate of MDS/sAML following fludarabine combination therapy is higher than that previously reported for fludarabine monotherapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Cohort Studies</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myelodysplastic Syndromes - chemically induced</subject><subject>Myelodysplastic Syndromes - epidemiology</subject><subject>Myelodysplastic Syndromes - therapy</subject><subject>Vidarabine - adverse effects</subject><subject>Vidarabine - analogs & derivatives</subject><issn>0390-6078</issn><issn>1592-8721</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFz8lqwzAUBVBRWpo07S8Ub0pXBknWuCyhEwSy8d482VKsIg9IDsZ_X0NSCg_u5nC57wZtCdc0V5KSW7TFhca5wFJt0ENKPxhTrLW8RxsisaKY0C06ltHC1Nl-yqMNMNkm6xYbhmZJY4DkIXNDCMPs-1PmwrmBCMb3NquHbk2Y_NBndWu7YWpthHF5RHcOQrJP19yh8uO93H_lh-Pn9_7tkLdUkilX1KyzuGBCOiUEMUY3GrAkTnBumFGWc1cQrLA0pOCYMS7BUVtz1TgGxQ49X2rHs-lsU43RdxCX6u-xFbxcAaQagovQ1z79O0UFw5ys7vXiWn9qZx9tlToIYa2l1TzPmlRkPc5E8QtnHWYy</recordid><startdate>20061101</startdate><enddate>20061101</enddate><creator>Tam, CS</creator><creator>Seymour, JF</creator><creator>Prince, HM</creator><creator>Kenealy, M</creator><creator>Wolf, M</creator><creator>Januszewicz, EH</creator><creator>Westerman, D</creator><general>Haematologica</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20061101</creationdate><title>Treatment-related myelodysplasia following fludarabine combination chemotherapy</title><author>Tam, CS ; Seymour, JF ; Prince, HM ; Kenealy, M ; Wolf, M ; Januszewicz, EH ; Westerman, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h271t-82b07856467f8661bb9d9a071f655b4b8e55f310807b13504457af2ec58df4a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Cohort Studies</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myelodysplastic Syndromes - chemically induced</topic><topic>Myelodysplastic Syndromes - epidemiology</topic><topic>Myelodysplastic Syndromes - therapy</topic><topic>Vidarabine - adverse effects</topic><topic>Vidarabine - analogs & derivatives</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tam, CS</creatorcontrib><creatorcontrib>Seymour, JF</creatorcontrib><creatorcontrib>Prince, HM</creatorcontrib><creatorcontrib>Kenealy, M</creatorcontrib><creatorcontrib>Wolf, M</creatorcontrib><creatorcontrib>Januszewicz, EH</creatorcontrib><creatorcontrib>Westerman, D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Haematologica (Roma)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tam, CS</au><au>Seymour, JF</au><au>Prince, HM</au><au>Kenealy, M</au><au>Wolf, M</au><au>Januszewicz, EH</au><au>Westerman, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment-related myelodysplasia following fludarabine combination chemotherapy</atitle><jtitle>Haematologica (Roma)</jtitle><addtitle>Haematologica</addtitle><date>2006-11-01</date><risdate>2006</risdate><volume>91</volume><issue>11</issue><spage>1546</spage><epage>1550</epage><pages>1546-1550</pages><issn>0390-6078</issn><eissn>1592-8721</eissn><abstract>Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Although myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) are rare following fludarabine monotherapy, the risk of these diseases may potentially be increased when fludarabine is combined with cyclophosphamide or mitoxantrone due to synergistic effects on the inhibition of DNA repair. Among 137 patients treated with fludarabine combination regimens, ten patients developed MDS/sAML, including one who had received no other therapy. Six patients had abnormalities of chromosomes 5 and/or 7. The crude rate of MDS/sAML was 2.5% for previously untreated patients, and 9.3% for pretreated patients (p=0.28). The rate of MDS/sAML following fludarabine combination therapy is higher than that previously reported for fludarabine monotherapy.</abstract><cop>Pavia</cop><pub>Haematologica</pub><pmid>17082012</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0390-6078 |
| ispartof | Haematologica (Roma), 2006-11, Vol.91 (11), p.1546-1550 |
| issn | 0390-6078 1592-8721 |
| language | eng |
| recordid | cdi_pubmed_primary_17082012 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Cohort Studies Drug Therapy, Combination Female Hematologic and hematopoietic diseases Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Myelodysplastic Syndromes - chemically induced Myelodysplastic Syndromes - epidemiology Myelodysplastic Syndromes - therapy Vidarabine - adverse effects Vidarabine - analogs & derivatives |
| title | Treatment-related myelodysplasia following fludarabine combination chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T04%3A37%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment-related%20myelodysplasia%20following%20fludarabine%20combination%20chemotherapy&rft.jtitle=Haematologica%20(Roma)&rft.au=Tam,%20CS&rft.date=2006-11-01&rft.volume=91&rft.issue=11&rft.spage=1546&rft.epage=1550&rft.pages=1546-1550&rft.issn=0390-6078&rft.eissn=1592-8721&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E17082012%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17082012&rfr_iscdi=true |